[Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005242
German
Original Title: Mirikizumab (Colitis Ulcerosa)
Details
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Colitis, Ulcerative
  • Antibodies, Monoclonal, Humanized
  • Anti-Inflammatory Agents, Non-Steroidal
  • Gastrointestinal Agents
  • Inflammatory Bowel Diseases
Keywords
  • Mirikizumab
  • Colitis – Ulcerative
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.